Derazantinib hydrochloride is under clinical development by Basilea Pharmaceutica International and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Derazantinib hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Derazantinib hydrochloride overview
Deranzantinib hydrchloride (ARQ-087) is under development for the treatment of intrahepatic cholangiocarcinoma (iCCA), adenocarcinoma of the gastroesophageal junction, adrenocortical tumors, advanced solid tumors and urothelial cell carcinoma. The drug candidate is administered orally. ARQ-087 is an inhibitor of pan-fibroblast growth factor receptor (FGFR) and CSF1R. The drug candidate is based on proprietary structure-based drug design technology known as the ArQule Kinase Inhibitor Platform (AKIP).
Basilea Pharmaceutica International overview
Basilea Pharmaceutica International, a subsidiary of Basilea Pharmaceutica Ltd, is a manufacturer and supplier of inorganic and organic medicinal chemicals.
For a complete picture of Derazantinib hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.